Home › NCT06824454

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult kidney transplant patients.
* No known contraindications to Dipyridamole

Exclusion Criteria:

* Contraindications to Dipyridamole.
* Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
* Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

About the study

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

What is being tested

• Dipyridamole 75 MG (drug)

Sponsor: Stanford University · Participants: 90 · Started: May 15, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06824454

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.